Gitta Boons | Principal Data Scientist
myNEO Therapeutics

Gitta Boons, Principal Data Scientist, myNEO Therapeutics

Gitta Boons studied Biochemistry and Biotechnology at the University of Antwerp, where she developed an early interest in cancer research. She conducted her Master’s thesis at the Laboratory for Translational Research and Microfluidics at Paris Descartes University and pursued an FWO-funded PhD in oncogenetics at the University of Antwerp. Her PhD research about (epi)genetic alterations as (liquid) cancer biomarkers sparked her interest in bioinformatics, which resulted in a BanaBa in Bioinformatics at the Howest. Since 2022, she has been working as a Data Scientist at myNEO Therapeutics, where she contributes to the development and refinement of the company’s neoantigen discovery pipeline. Her work focuses on advancing computational approaches for personalized cancer immunotherapies, while also leading and supporting a broad range of internal and collaborative projects.

Appearances:



Festival of Biologics Day 2 @ 17:10

Camyotopes: Next-Generation Immunotherapy Targets and their Development into an mRNA-LNP Colorectal Vaccine

  • Dark genome immunotherapy target discovery based on profiling over 1500+ tumor biopts and TME evaluations
  • Identification of highly-shared, presented, tumor-specific "camyopeptides"
  • First glance at immunological responses revealing first-in-class potential of shared tumor targets
  • Deals & product pipeline in CRC: mRNA-LNP vaccine
last published: 22/Aug/25 15:25 GMT

back to speakers

Get involved at Festival of Biologics Basel 2025

 

 

TO SPONSOR


Derek Cavanagh

Derek.Cavanagh@terrapinn.com

 

Jack Bebb
Jack.Bebb@terrapinn.com

 

TO SPEAK


Jack Beard
Jack.Beard@terrapinn.com

 

MARKETING & PRESS


Ollie McDaid

ollie.mcdaid@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.